Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience.
Identifieur interne : 000C05 ( Main/Corpus ); précédent : 000C04; suivant : 000C06Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience.
Auteurs : Waleed Al-Darzi ; Lindsey Aurora ; Alexander Michaels ; Jennifer Cowger ; Gillian Grafton ; Yelena Selektor ; Cristina Tita ; Bashar Hannawi ; David Lanfear ; Hassan W. Nemeh ; Celeste T. WilliamsSource :
- Clinical transplantation [ 1399-0012 ] ; 2020.
English descriptors
- KwdEn :
- Adult (MeSH), Aged (MeSH), COVID-19 (diagnosis), COVID-19 (etiology), COVID-19 (immunology), COVID-19 (therapy), COVID-19 Testing (MeSH), Combined Modality Therapy (MeSH), Female (MeSH), Graft Rejection (prevention & control), Heart Transplantation (MeSH), Hospitalization (MeSH), Humans (MeSH), Immunocompromised Host (MeSH), Immunosuppressive Agents (adverse effects), Immunosuppressive Agents (therapeutic use), Male (MeSH), Michigan (MeSH), Middle Aged (MeSH), Postoperative Complications (diagnosis), Postoperative Complications (immunology), Postoperative Complications (therapy), Postoperative Complications (virology), Retrospective Studies (MeSH), Severity of Illness Index (MeSH), Treatment Outcome (MeSH).
- MESH :
- chemical , adverse effects : Immunosuppressive Agents.
- geographic : Michigan.
- diagnosis : COVID-19, Postoperative Complications.
- etiology : COVID-19.
- immunology : COVID-19, Postoperative Complications.
- prevention & control : Graft Rejection.
- chemical , therapeutic use : Immunosuppressive Agents.
- therapy : COVID-19, Postoperative Complications.
- virology : Postoperative Complications.
- Adult, Aged, COVID-19 Testing, Combined Modality Therapy, Female, Heart Transplantation, Hospitalization, Humans, Immunocompromised Host, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Treatment Outcome.
Abstract
A chronic immunosuppressed state as in solid organ transplant recipients is a reported risk factor for the novel 2019 coronavirus infection. Patients with a history of orthotopic heart transplant (OHT) at a tertiary care transplant center in Detroit, Michigan were retrospectively reviewed from March until May 2020. Clinical parameters and outcomes of 5 OHT recipients and one combined heart-lung recipient with confirmed SARS-CoV-2 were obtained. The cohort was predominately African American males with median age of 59 years (interquartile range, 48.25-73.25). All patients were classified as having mild-moderate disease; none required intubation or ICU admission with no deaths. The most common presenting symptoms were fever and shortness of breath 83% (n = 5), followed by cough and chills 67% (n = 4). All admitted patients (n = 5) received hydroxychloroquine and 3 received high-dose steroids. Antimetabolites were held for 2 patients (33.3%). The calcineurin inhibitor trough goal was decreased in only 1 patient; 3 other patients, without change in goal, required calcineurin inhibitor dosage reduction. Two patients requiring readmission presented 7 and 23 days after initial symptoms onset. In conclusion, our experience with OHT patients infected by the SARS-CoV-2 virus did not have an elevated risk of severe infection. Impact of modifying immunosuppression remains unclear.
DOI: 10.1111/ctr.14091
PubMed: 32940925
Links to Exploration step
pubmed:32940925Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience.</title><author><name sortKey="Al Darzi, Waleed" sort="Al Darzi, Waleed" uniqKey="Al Darzi W" first="Waleed" last="Al-Darzi">Waleed Al-Darzi</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aurora, Lindsey" sort="Aurora, Lindsey" uniqKey="Aurora L" first="Lindsey" last="Aurora">Lindsey Aurora</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Michaels, Alexander" sort="Michaels, Alexander" uniqKey="Michaels A" first="Alexander" last="Michaels">Alexander Michaels</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cowger, Jennifer" sort="Cowger, Jennifer" uniqKey="Cowger J" first="Jennifer" last="Cowger">Jennifer Cowger</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Grafton, Gillian" sort="Grafton, Gillian" uniqKey="Grafton G" first="Gillian" last="Grafton">Gillian Grafton</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Selektor, Yelena" sort="Selektor, Yelena" uniqKey="Selektor Y" first="Yelena" last="Selektor">Yelena Selektor</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tita, Cristina" sort="Tita, Cristina" uniqKey="Tita C" first="Cristina" last="Tita">Cristina Tita</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hannawi, Bashar" sort="Hannawi, Bashar" uniqKey="Hannawi B" first="Bashar" last="Hannawi">Bashar Hannawi</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lanfear, David" sort="Lanfear, David" uniqKey="Lanfear D" first="David" last="Lanfear">David Lanfear</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nemeh, Hassan W" sort="Nemeh, Hassan W" uniqKey="Nemeh H" first="Hassan W" last="Nemeh">Hassan W. Nemeh</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Williams, Celeste T" sort="Williams, Celeste T" uniqKey="Williams C" first="Celeste T" last="Williams">Celeste T. Williams</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2020">2020</date><idno type="RBID">pubmed:32940925</idno><idno type="pmid">32940925</idno><idno type="doi">10.1111/ctr.14091</idno><idno type="wicri:Area/Main/Corpus">000C05</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000C05</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience.</title><author><name sortKey="Al Darzi, Waleed" sort="Al Darzi, Waleed" uniqKey="Al Darzi W" first="Waleed" last="Al-Darzi">Waleed Al-Darzi</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Aurora, Lindsey" sort="Aurora, Lindsey" uniqKey="Aurora L" first="Lindsey" last="Aurora">Lindsey Aurora</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Michaels, Alexander" sort="Michaels, Alexander" uniqKey="Michaels A" first="Alexander" last="Michaels">Alexander Michaels</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Cowger, Jennifer" sort="Cowger, Jennifer" uniqKey="Cowger J" first="Jennifer" last="Cowger">Jennifer Cowger</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Grafton, Gillian" sort="Grafton, Gillian" uniqKey="Grafton G" first="Gillian" last="Grafton">Gillian Grafton</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Selektor, Yelena" sort="Selektor, Yelena" uniqKey="Selektor Y" first="Yelena" last="Selektor">Yelena Selektor</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Tita, Cristina" sort="Tita, Cristina" uniqKey="Tita C" first="Cristina" last="Tita">Cristina Tita</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Hannawi, Bashar" sort="Hannawi, Bashar" uniqKey="Hannawi B" first="Bashar" last="Hannawi">Bashar Hannawi</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lanfear, David" sort="Lanfear, David" uniqKey="Lanfear D" first="David" last="Lanfear">David Lanfear</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Nemeh, Hassan W" sort="Nemeh, Hassan W" uniqKey="Nemeh H" first="Hassan W" last="Nemeh">Hassan W. Nemeh</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Williams, Celeste T" sort="Williams, Celeste T" uniqKey="Williams C" first="Celeste T" last="Williams">Celeste T. Williams</name><affiliation><nlm:affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Clinical transplantation</title><idno type="eISSN">1399-0012</idno><imprint><date when="2020" type="published">2020</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>COVID-19 (diagnosis)</term><term>COVID-19 (etiology)</term><term>COVID-19 (immunology)</term><term>COVID-19 (therapy)</term><term>COVID-19 Testing (MeSH)</term><term>Combined Modality Therapy (MeSH)</term><term>Female (MeSH)</term><term>Graft Rejection (prevention & control)</term><term>Heart Transplantation (MeSH)</term><term>Hospitalization (MeSH)</term><term>Humans (MeSH)</term><term>Immunocompromised Host (MeSH)</term><term>Immunosuppressive Agents (adverse effects)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Male (MeSH)</term><term>Michigan (MeSH)</term><term>Middle Aged (MeSH)</term><term>Postoperative Complications (diagnosis)</term><term>Postoperative Complications (immunology)</term><term>Postoperative Complications (therapy)</term><term>Postoperative Complications (virology)</term><term>Retrospective Studies (MeSH)</term><term>Severity of Illness Index (MeSH)</term><term>Treatment Outcome (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Michigan</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>COVID-19</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>COVID-19</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Graft Rejection</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Immunosuppressive Agents</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term><term>Postoperative Complications</term></keywords><keywords scheme="MESH" qualifier="virology" xml:lang="en"><term>Postoperative Complications</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adult</term><term>Aged</term><term>COVID-19 Testing</term><term>Combined Modality Therapy</term><term>Female</term><term>Heart Transplantation</term><term>Hospitalization</term><term>Humans</term><term>Immunocompromised Host</term><term>Male</term><term>Middle Aged</term><term>Retrospective Studies</term><term>Severity of Illness Index</term><term>Treatment Outcome</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A chronic immunosuppressed state as in solid organ transplant recipients is a reported risk factor for the novel 2019 coronavirus infection. Patients with a history of orthotopic heart transplant (OHT) at a tertiary care transplant center in Detroit, Michigan were retrospectively reviewed from March until May 2020. Clinical parameters and outcomes of 5 OHT recipients and one combined heart-lung recipient with confirmed SARS-CoV-2 were obtained. The cohort was predominately African American males with median age of 59 years (interquartile range, 48.25-73.25). All patients were classified as having mild-moderate disease; none required intubation or ICU admission with no deaths. The most common presenting symptoms were fever and shortness of breath 83% (n = 5), followed by cough and chills 67% (n = 4). All admitted patients (n = 5) received hydroxychloroquine and 3 received high-dose steroids. Antimetabolites were held for 2 patients (33.3%). The calcineurin inhibitor trough goal was decreased in only 1 patient; 3 other patients, without change in goal, required calcineurin inhibitor dosage reduction. Two patients requiring readmission presented 7 and 23 days after initial symptoms onset. In conclusion, our experience with OHT patients infected by the SARS-CoV-2 virus did not have an elevated risk of severe infection. Impact of modifying immunosuppression remains unclear.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32940925</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>04</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>04</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1399-0012</ISSN><JournalIssue CitedMedium="Internet"><Volume>34</Volume><Issue>12</Issue><PubDate><Year>2020</Year><Month>12</Month></PubDate></JournalIssue><Title>Clinical transplantation</Title><ISOAbbreviation>Clin Transplant</ISOAbbreviation></Journal><ArticleTitle>Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience.</ArticleTitle><Pagination><MedlinePgn>e14091</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1111/ctr.14091</ELocationID><Abstract><AbstractText>A chronic immunosuppressed state as in solid organ transplant recipients is a reported risk factor for the novel 2019 coronavirus infection. Patients with a history of orthotopic heart transplant (OHT) at a tertiary care transplant center in Detroit, Michigan were retrospectively reviewed from March until May 2020. Clinical parameters and outcomes of 5 OHT recipients and one combined heart-lung recipient with confirmed SARS-CoV-2 were obtained. The cohort was predominately African American males with median age of 59 years (interquartile range, 48.25-73.25). All patients were classified as having mild-moderate disease; none required intubation or ICU admission with no deaths. The most common presenting symptoms were fever and shortness of breath 83% (n = 5), followed by cough and chills 67% (n = 4). All admitted patients (n = 5) received hydroxychloroquine and 3 received high-dose steroids. Antimetabolites were held for 2 patients (33.3%). The calcineurin inhibitor trough goal was decreased in only 1 patient; 3 other patients, without change in goal, required calcineurin inhibitor dosage reduction. Two patients requiring readmission presented 7 and 23 days after initial symptoms onset. In conclusion, our experience with OHT patients infected by the SARS-CoV-2 virus did not have an elevated risk of severe infection. Impact of modifying immunosuppression remains unclear.</AbstractText><CopyrightInformation>© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Al-Darzi</LastName><ForeName>Waleed</ForeName><Initials>W</Initials><Identifier Source="ORCID">0000-0002-2324-8186</Identifier><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aurora</LastName><ForeName>Lindsey</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michaels</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cowger</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grafton</LastName><ForeName>Gillian</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Selektor</LastName><ForeName>Yelena</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tita</LastName><ForeName>Cristina</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hannawi</LastName><ForeName>Bashar</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lanfear</LastName><ForeName>David</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nemeh</LastName><ForeName>Hassan W</ForeName><Initials>HW</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Williams</LastName><ForeName>Celeste T</ForeName><Initials>CT</Initials><AffiliationInfo><Affiliation>Heart and Vascular Institute, Henry Ford Hospital, Detroit, MI, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R01HL132154</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>R01HL132154</GrantID><Acronym>NH</Acronym><Agency>NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>10</Month><Day>01</Day></ArticleDate></Article><MedlineJournalInfo><Country>Denmark</Country><MedlineTA>Clin Transplant</MedlineTA><NlmUniqueID>8710240</NlmUniqueID><ISSNLinking>0902-0063</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086742" MajorTopicYN="N">COVID-19 Testing</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003131" MajorTopicYN="N">Combined Modality Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006084" MajorTopicYN="N">Graft Rejection</DescriptorName><QualifierName UI="Q000517" MajorTopicYN="N">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016027" MajorTopicYN="Y">Heart Transplantation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016867" MajorTopicYN="Y">Immunocompromised Host</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008824" MajorTopicYN="N" Type="Geographic">Michigan</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">COVID-19</Keyword><Keyword MajorTopicYN="Y">SARS-CoV-2</Keyword><Keyword MajorTopicYN="Y">global pandemic</Keyword><Keyword MajorTopicYN="Y">heart transplant recipients</Keyword><Keyword MajorTopicYN="Y">immunosuppression</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>01</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>08</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>09</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>9</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>9</Month><Day>17</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32940925</ArticleId><ArticleId IdType="doi">10.1111/ctr.14091</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382:727-733.</Citation></Reference><Reference><Citation>Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review. JAMA. 2020;323(18):1824-1836.</Citation></Reference><Reference><Citation>WHO. COVID-19 Situation Reports. World Health Organization. May 24, 2020. https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports/</Citation></Reference><Reference><Citation>Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458-464.</Citation></Reference><Reference><Citation>Kates OS, Fisher CE, Stankiewicz-Karita HC, et al. Earliest cases of coronavirus disease 2019 (COVID-19) identified in solid organ transplant recipients in the United States. Am J Transplant. 2020;20(7):1885-1890.</Citation></Reference><Reference><Citation>Li F, Cai J, Dong N. First cases of COVID-19 in heart transplantation from China. J Heart Lung Transplant. 2020;39:496-497.</Citation></Reference><Reference><Citation>Holzhauser L, Lourenco L, Sarswat N, Kim G, Chung B, Nguyen AB. Early experience of COVID-19 in two heart transplant recipients: case reports and review of treatment options. Am J Transplant. 2020;20(10):2916-2922.</Citation></Reference><Reference><Citation>Pereira MR, Mohan S, Cohen DJ, et al. COVID-19 in solid organ transplant recipients: Initial report from the US epicenter. Am J Transplant. 2020;20(7):1800-1808.</Citation></Reference><Reference><Citation>Latif F, Farr MA, Clerkin KJ, et al. Characteristics and outcomes of recipients of heart transplant with coronavirus disease 2019. JAMA Cardiology. 2020;5(10):1165-1169.</Citation></Reference><Reference><Citation>Michigan.gov. Michigan Data/Coronavirus. https://www.michigan.gov/coronavirus/0,9753,7-406-98163_9817300.html. Accessed May 27, 2020.</Citation></Reference><Reference><Citation>Bialek S, Boundy E, Bowen V, et al. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) - United States, February 12-March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343-346.</Citation></Reference><Reference><Citation>Khan IH, Zahra SA, Zaim S, Harky A. At the heart of COVID-19. J Card Surg. 2020;35:1287-1294.</Citation></Reference><Reference><Citation>CDC. COVID-19 in Racial and Ethnic Minority Groups. Centers for Disease Control and Prevention. May 24, 2020. https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/racial-ethnic-minorities.html</Citation></Reference><Reference><Citation>Chen G, Wu D, Guo W, et al. Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020;130:2620-2629.</Citation></Reference><Reference><Citation>Zhao M. Cytokine storm and immunomodulatory therapy in COVID-19: Role of chloroquine and anti-IL-6 monoclonal antibodies. Int J Antimicrob Agents. 2020;55;105982.</Citation></Reference><Reference><Citation>Willicombe M, Thomas D, McAdoo S. COVID-19 and calcineurin inhibitors: should they get left out in the storm? J Am Soc Nephrol. 2020;31:1145-1146.</Citation></Reference><Reference><Citation>Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395:1033-1034.</Citation></Reference></ReferenceList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000C05 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd -nk 000C05 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Corpus
|type= RBID
|clé= pubmed:32940925
|texte= Heart transplant recipients with confirmed 2019 novel coronavirus infection: The Detroit experience.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Corpus/RBID.i -Sk "pubmed:32940925" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |